Neuron-specific enolase as a tumor marker in metastatic melanoma. 1994

A C Buzaid, and A B Sandler, and C L Hayden, and J Scinto, and W J Poo, and M B Clark, and S Hotchkiss
University of Texas M. D. Anderson Cancer Center, Department of Melanoma/Sarcoma, Houston 77030.

Neuron-specific enolase (NSE) has been shown by some investigators to be a useful tumor marker for melanoma, but the relationship between NSE and tumor burden has not been extensively studied. We therefore examined NSE levels in 240 patients of whom 169 had no clinical evidence of disease (NED) and 71 had metastatic disease. There was no statistically significant difference in NSE levels in patients with NED compared with metastatic disease as well as those with high tumor burden compared with low or intermediate tumor burden. In addition, the mean absolute values of NSE, despite a slight elevation with tumor burden, were within the normal range (< 20 ng/ml). Our data suggest that NSE levels measured by the method used in our study are of no benefit in melanoma.

UI MeSH Term Description Entries
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D010751 Phosphopyruvate Hydratase A hydro-lyase that catalyzes the dehydration of 2-phosphoglycerate to form PHOSPHOENOLPYRUVATE. Several different isoforms of this enzyme exist, each with its own tissue specificity. Enolase,Neuron-Specific Enolase,2-Phospho-D-Glycerate Hydro-Lyase,2-Phospho-D-Glycerate Hydrolase,2-Phosphoglycerate Dehydratase,Enolase 2,Enolase 3,Muscle-Specific Enolase,Nervous System-Specific Enolase,Non-Neuronal Enolase,alpha-Enolase,beta-Enolase,gamma-Enolase,2 Phospho D Glycerate Hydro Lyase,2 Phospho D Glycerate Hydrolase,2 Phosphoglycerate Dehydratase,Dehydratase, 2-Phosphoglycerate,Enolase, Muscle-Specific,Enolase, Nervous System-Specific,Enolase, Neuron-Specific,Enolase, Non-Neuronal,Hydratase, Phosphopyruvate,Hydro-Lyase, 2-Phospho-D-Glycerate,Muscle Specific Enolase,Nervous System Specific Enolase,Neuron Specific Enolase,Non Neuronal Enolase,System-Specific Enolase, Nervous,alpha Enolase,beta Enolase,gamma Enolase
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

A C Buzaid, and A B Sandler, and C L Hayden, and J Scinto, and W J Poo, and M B Clark, and S Hotchkiss
October 2020, The Journal of dermatology,
A C Buzaid, and A B Sandler, and C L Hayden, and J Scinto, and W J Poo, and M B Clark, and S Hotchkiss
December 1994, Harefuah,
A C Buzaid, and A B Sandler, and C L Hayden, and J Scinto, and W J Poo, and M B Clark, and S Hotchkiss
August 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
A C Buzaid, and A B Sandler, and C L Hayden, and J Scinto, and W J Poo, and M B Clark, and S Hotchkiss
February 1992, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
A C Buzaid, and A B Sandler, and C L Hayden, and J Scinto, and W J Poo, and M B Clark, and S Hotchkiss
October 1993, Lancet (London, England),
A C Buzaid, and A B Sandler, and C L Hayden, and J Scinto, and W J Poo, and M B Clark, and S Hotchkiss
January 1992, European journal of cancer (Oxford, England : 1990),
A C Buzaid, and A B Sandler, and C L Hayden, and J Scinto, and W J Poo, and M B Clark, and S Hotchkiss
January 1995, Journal of Tongji Medical University = Tong ji yi ke da xue xue bao,
A C Buzaid, and A B Sandler, and C L Hayden, and J Scinto, and W J Poo, and M B Clark, and S Hotchkiss
November 1989, Journal of the National Cancer Institute,
A C Buzaid, and A B Sandler, and C L Hayden, and J Scinto, and W J Poo, and M B Clark, and S Hotchkiss
November 1988, Deutsche medizinische Wochenschrift (1946),
A C Buzaid, and A B Sandler, and C L Hayden, and J Scinto, and W J Poo, and M B Clark, and S Hotchkiss
December 1990, Lancet (London, England),
Copied contents to your clipboard!